ESHAP

ESHAP is a combination chemotherapy regimen used primarily as salvage therapy for relapsed or refractory lymphomas, including non-Hodgkin lymphoma, Hodgkin lymphoma, and sometimes myeloma. The acronym stands for its four components: - Etoposide (a topoisomerase II inhibitor) - Solu-Medrol (methylprednisolone; a glucocorticoid steroid) - High-dose Ara-C (cytarabine; an antimetabolite) - Cisplatin (a platinum-based alkylating agent) Etoposide, cytarabine, and cisplatin are cytotoxic agents that destroy rapidly dividing cells such as cancer cells. Methylprednisolone is a corticosteroid that suppresses immune response and can directly induce apoptosis in certain lymphoid malignancies. The regimen is typically administered intravenously over several days per cycle and may be used before autologous stem cell transplantation. ESHAP may also be combined with rituximab in some cases (R-ESHAP), but the canonical "ESHAP" does not include rituximab[1][2][3][5][6].

Other names

etoposide + methylprednisolone + cytarabine + cisplatinE-SHAP